top | item 47083201

(no title)

bradleyjg | 10 days ago

All that may well be true. But one doesn’t have to be a leader in the field of genomics to have read decades of articles breathlessly proclaiming medical breakthroughs (in mice) and then not ever seeing them hit the market (in humans.)

Or in other words the meat of the critique is not aimed at genomics, but rather in science marketing.

discuss

order

alephnerd|10 days ago

You can say the same thing about Phase 1 to 3 as well.

The reality is every theraputic has some kind of negative side effect, which may reduce the incentive for it to be productionized becuase the whole point about medicine is harm reduction.

Passing the hurdle of being viable in mice is a major hurdle because in most cases, experiments fail. And if it's efficacy is proven in mice, it shows viability in a specific approach and justifies investing the hundreds of millions of dollars in trying to bring something to Phase 3.

jalapenos|10 days ago

That's the point though - why does it take hundreds of millions of dollars for phase 3?

Because it happens in a regime that intentionally makes it so.

That's not how e.g. vaccination got invented now is it.

Busy-bodies too busy "protecting us from ourselves" to let us find cures.